ArticlePloS one2026
Quantitative assessment of china's policies on the online sale of prescription drugs.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Against the dual backdrop of the rapid advancement of big data-driven healthcare and the COVID-19 pandemic, China has gradually relaxed restrictions on the online sale of prescription drugs. However, the regulatory framework governing this sector remains in its early stage of development, and existing policy gaps pose substantial risks to public medication safety, highlighting the urgent need for further policy refinement. This study quantitatively analyzed China's policies on the online sale of prescription drugs, thus providing valuable insights for the development and improvement of future policies. Using ROST CM6.0, text mining was conducted on 18 policies governing the online sale of prescription drugs issued between 1999 and 2023. A Policy Model Consistency (PMC) model was established based on 10 primary variables and 35 secondary variables. The analysis yielded an average PMC index of 6.28, resulting in an overall policy rating of "good." Among the 18 policies, 6 were classified as excellent and 12 as good, with no policies rated as perfect or unqualified. Amid the continuous exploration of policy and reforms, China's policy system for the online sale of prescription drugs has been gradually improved. Current policies place strong emphasis on the efficiency of smart approaches and the steady development of an intelligent regulatory system. However, considerable opportunities for optimization remains in key areas, including the whole-process regulatory system for the online sale of prescription drugs, the collaborative participation of medical institutions, and the standardized governance of third-party platforms. Future policies should focus on the regulations governing the online sale of prescription drugs by clarifying the boundaries, rights and responsibilities of each subject while refining and standardizing their code of conduct. Multidepartment collaboration should also be strengthened by encouraging industry associations in the development of an intelligent regulatory team, thereby promoting the establishment of a three-dimensional digital regulatory pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.